ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Penem Antibiotics Market Outlook, In‑Depth Analysis & Forecast to 2031
Published Date: November 2025
|
Report Code: QYRE-Auto-31D17017
Home | Market Reports | Health| Health Conditions| Infectious Diseases
Global Penem Antibiotics Market Research Report 2024
BUY CHAPTERS

Global Penem Antibiotics Market Outlook, In‑Depth Analysis & Forecast to 2031

Code: QYRE-Auto-31D17017
Report
November 2025
Pages:153
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Sumitomo Pharma
Merck Sharp & Dohme
Savior Lifetec
ACS Dobfar
Pfizer Inc
Eugia Pharma
Venus Remedies
Sun Pharmaceutical
JW Pharmaceutical
Aurobindo Pharma
Daiichi Sankyo
Maruho
Taiwan Biotech
Shenzhen Haibin Pharmaceutical
Zhejiang Hisun Pharmaceutical
Cspc Holdings
Zhuhai United Laboratories
Haikou Pharmaceutical Factory
Jiangsu Simcere Pharmaceutical
Chia Tai Tianqing Pharmaceuticals
Merck Sharp & Dohme

Penem Antibiotics Market

The global Penem Antibiotics market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications.
Penem Antibiotics (Carbapenems) are a class of very effective antibiotic agents most commonly used for treatment of severe bacterial infections. This class of antibiotics is usually reserved for known or suspected multidrug-resistant (MDR) bacterial infections. Similar to penicillins and cephalosporins, carbapenems are members of the beta-lactam antibiotics drug class, which kill bacteria by binding to penicillin-binding proteins, thus inhibiting bacterial cell wall synthesis. However, these agents individually exhibit a broader spectrum of activity compared to most cephalosporins and penicillins. Furthermore, carbapenems are typically unaffected by emerging antibiotic resistance, even to other beta-lactams.
From a downstream perspective, Hospital accounted for % of 2024 revenue, surging to US$ million by 2031 (CAGR: % from 2025–2031).
Penem Antibiotics leading manufacturers including Sumitomo Pharma, Merck Sharp & Dohme, Savior Lifetec, ACS Dobfar, Pfizer, Eugia Pharma, Venus Remedies, Sun Pharmaceutical, JW Pharmaceutical, Aurobindo Pharma, etc., dominate supply; the top five capture approximately % of global revenue, with Sumitomo Pharma leading 2024 sales at US$ million.
Regional Outlook:
North America rose from US$ million in 2024 to a forecast US$ million by 2031 (CAGR %).
Asia‑Pacific will expand from US$ million to US$ million (CAGR  %), led by China (US$ million in 2024, % share rising to % by 2031), Japan (CAGR %), South Korea (CAGR %), and Southeast Asia (CAGR %).
Europe is set to grow from US$ million to US$ million (CAGR %), with Germany projected to hit US$ million by 2031 (CAGR %).

Report Includes:

This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Penem Antibiotics market across value chain. It analyzes historical revenue data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.
Critical competitive intelligence profiles players—revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise Industry‑chain overview maps upstream, middlestream, and downstream distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation

Scope of Penem Antibiotics Market Report

Report Metric Details
Report Name Penem Antibiotics Market
Segment by Type
  • Meropenem
  • Imipenem
  • Biapenem
  • Ertapenem
  • Others
Segment by Application
  • Hospital
  • Clinic
  • Others
Sales by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Sumitomo Pharma, Merck Sharp & Dohme, Savior Lifetec, ACS Dobfar, Pfizer, Eugia Pharma, Venus Remedies, Sun Pharmaceutical, JW Pharmaceutical, Aurobindo Pharma, Daiichi Sankyo, Maruho, Taiwan Biotech, Shenzhen Haibin Pharmaceutical, Zhejiang Hisun Pharmaceutical, Cspc Holdings, Zhuhai United Laboratories, Haikou Pharmaceutical Factory, Chia Tai Tianqing Pharmaceuticals, Jiangsu Simcere Pharmaceutical
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Defines the Penem Antibiotics study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
  • Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
  • Chapter 3: Dissects the player landscape—ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves.
  • Chapter 4: Unlocks high margin product segments—compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
  • Chapter 5: Targets downstream market opportunities—evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
  • Chapter 6: North America—breaks down market size by Type, by Application and country, profiles key players and assesses growth drivers and barriers.
  • Chapter 7: Europe—analyses regional market by Type, by Application and players, flagging drivers and barriers.
  • Chapter 8: Asia Pacific—quantifies market size by Type, by Application, and region/country, profiles top players, and uncovers high potential expansion areas.
  • Chapter 9: Central & South America—measures market size by Type, by Application, and country, profiles top players, and identifies investment opportunities and challenges.
  • Chapter 10: Middle East and Africa—evaluates market size by Type, by Application, and country, profiles key players, and outlines investment prospects and market hurdles
  • Chapter 11: Profiles players in depth—details product specs, revenue, margins; Top-tier players 2024 sales breakdowns by Product type, by Application, by region SWOT analysis, and recent strategic developments.
  • Chapter 12: Industry chain—analyses upstream, cost drivers, plus downstream channels.
  • Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
  • Chapter 14: Actionable conclusions and strategic recommendations.
  • Why This Report:
  • Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
  • Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
  • Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
  • Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
  • Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
  • Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

FAQ for this report

Who are the main players in the Penem Antibiotics Market report?

Ans: The main players in the Penem Antibiotics Market are Sumitomo Pharma, Merck Sharp & Dohme, Savior Lifetec, ACS Dobfar, Pfizer, Eugia Pharma, Venus Remedies, Sun Pharmaceutical, JW Pharmaceutical, Aurobindo Pharma, Daiichi Sankyo, Maruho, Taiwan Biotech, Shenzhen Haibin Pharmaceutical, Zhejiang Hisun Pharmaceutical, Cspc Holdings, Zhuhai United Laboratories, Haikou Pharmaceutical Factory, Chia Tai Tianqing Pharmaceuticals, Jiangsu Simcere Pharmaceutical

What are the Application segmentation covered in the Penem Antibiotics Market report?

Ans: The Applications covered in the Penem Antibiotics Market report are Hospital, Clinic, Others

What are the Type segmentation covered in the Penem Antibiotics Market report?

Ans: The Types covered in the Penem Antibiotics Market report are Meropenem, Imipenem, Biapenem, Ertapenem, Others

1 Study Coverage
1.1 Introduction to Penem Antibiotics: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Penem Antibiotics Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Meropenem
1.2.3 Imipenem
1.2.4 Biapenem
1.2.5 Ertapenem
1.2.6 Others
1.3 Market Segmentation by Application
1.3.1 Global Penem Antibiotics Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Penem Antibiotics Revenue Estimates and Forecasts 2020-2031
2.2 Global Penem Antibiotics Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020-2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends
3 Competition by Players
3.1 Global Penem Antibiotics Player Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2020-2025)
3.1.2 Global Key Player Revenue Ranking (2023 vs. 2024)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Player (2020 VS 2024)
3.2 Global Penem Antibiotics Companies Headquarters and Service Footprint
3.3 Main Product Type Market Size by Players
3.3.1 Meropenem Market Size by Players
3.3.2 Imipenem Market Size by Players
3.3.3 Biapenem Market Size by Players
3.3.4 Ertapenem Market Size by Players
3.3.5 Others Market Size by Players
3.4 Global Penem Antibiotics Market Concentration and Dynamics
3.4.1 Global Market Concentration (CR5 and HHI)
3.4.2 Entrant/Exit Impact Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Penem Antibiotics Revenue Trends by Type
4.1.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.1.2 Global Revenue Market Share by Type (2020-2031)
4.2 Key Product Attributes and Differentiation
4.3 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.3.1 High-Growth Niches and Adoption Drivers
4.3.2 Profitability Hotspots and Cost Drivers
4.3.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Penem Antibiotics Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.1.2 Revenue Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application
6 North America
6.1 North America Market Size (2020-2031)
6.2 North America Key Players Revenue in 2024
6.3 North America Penem Antibiotics Market Size by Type (2020-2031)
6.4 North America Penem Antibiotics Market Size by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Penem Antibiotics Market Size by Country
6.6.1 North America Revenue Trends by Country
6.6.2 US
6.6.3 Canada
6.6.4 Mexico
7 Europe
7.1 Europe Market Size (2020-2031)
7.2 Europe Key Players Revenue in 2024
7.3 Europe Penem Antibiotics Market Size by Type (2020-2031)
7.4 Europe Penem Antibiotics Market Size by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Penem Antibiotics Market Size by Country
7.6.1 Europe Revenue Trends by Country
7.6.2 Germany
7.6.3 France
7.6.4 U.K.
7.6.5 Italy
7.6.6 Russia
8 Asia-Pacific
8.1 Asia-Pacific Market Size (2020-2031)
8.2 Asia-Pacific Key Players Revenue in 2024
8.3 Asia-Pacific Penem Antibiotics Market Size by Type (2020-2031)
8.4 Asia-Pacific Penem Antibiotics Market Size by Application (2020-2031)
8.5 Asia-Pacific Growth Accelerators and Market Barriers
8.6 Asia-Pacific Penem Antibiotics Market Size by Region
8.6.1 Asia-Pacific Revenue Trends by Region
8.7 China
8.8 Japan
8.9 South Korea
8.10 Australia
8.11 India
8.12 Southeast Asia
8.12.1 Indonesia
8.12.2 Vietnam
8.12.3 Malaysia
8.12.4 Philippines
8.12.5 Singapore
9 Central and South America
9.1 Central and South America Market Size (2020-2031)
9.2 Central and South America Key Players Revenue in 2024
9.3 Central and South America Penem Antibiotics Market Size by Type (2020-2031)
9.4 Central and South America Penem Antibiotics Market Size by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Penem Antibiotics Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Market Size (2020-2031)
10.2 Middle East and Africa Key Players Revenue in 2024
10.3 Middle East and Africa Penem Antibiotics Market Size by Type (2020-2031)
10.4 Middle East and Africa Penem Antibiotics Market Size by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Penem Antibiotics Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Israel
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Sumitomo Pharma
11.1.1 Sumitomo Pharma Corporation Information
11.1.2 Sumitomo Pharma Business Overview
11.1.3 Sumitomo Pharma Penem Antibiotics Product Features and Attributes
11.1.4 Sumitomo Pharma Penem Antibiotics Revenue and Gross Margin (2020-2025)
11.1.5 Sumitomo Pharma Penem Antibiotics Revenue by Product in 2024
11.1.6 Sumitomo Pharma Penem Antibiotics Revenue by Application in 2024
11.1.7 Sumitomo Pharma Penem Antibiotics Revenue by Geographic Area in 2024
11.1.8 Sumitomo Pharma Penem Antibiotics SWOT Analysis
11.1.9 Sumitomo Pharma Recent Developments
11.2 Merck Sharp & Dohme
11.2.1 Merck Sharp & Dohme Corporation Information
11.2.2 Merck Sharp & Dohme Business Overview
11.2.3 Merck Sharp & Dohme Penem Antibiotics Product Features and Attributes
11.2.4 Merck Sharp & Dohme Penem Antibiotics Revenue and Gross Margin (2020-2025)
11.2.5 Merck Sharp & Dohme Penem Antibiotics Revenue by Product in 2024
11.2.6 Merck Sharp & Dohme Penem Antibiotics Revenue by Application in 2024
11.2.7 Merck Sharp & Dohme Penem Antibiotics Revenue by Geographic Area in 2024
11.2.8 Merck Sharp & Dohme Penem Antibiotics SWOT Analysis
11.2.9 Merck Sharp & Dohme Recent Developments
11.3 Savior Lifetec
11.3.1 Savior Lifetec Corporation Information
11.3.2 Savior Lifetec Business Overview
11.3.3 Savior Lifetec Penem Antibiotics Product Features and Attributes
11.3.4 Savior Lifetec Penem Antibiotics Revenue and Gross Margin (2020-2025)
11.3.5 Savior Lifetec Penem Antibiotics Revenue by Product in 2024
11.3.6 Savior Lifetec Penem Antibiotics Revenue by Application in 2024
11.3.7 Savior Lifetec Penem Antibiotics Revenue by Geographic Area in 2024
11.3.8 Savior Lifetec Penem Antibiotics SWOT Analysis
11.3.9 Savior Lifetec Recent Developments
11.4 ACS Dobfar
11.4.1 ACS Dobfar Corporation Information
11.4.2 ACS Dobfar Business Overview
11.4.3 ACS Dobfar Penem Antibiotics Product Features and Attributes
11.4.4 ACS Dobfar Penem Antibiotics Revenue and Gross Margin (2020-2025)
11.4.5 ACS Dobfar Penem Antibiotics Revenue by Product in 2024
11.4.6 ACS Dobfar Penem Antibiotics Revenue by Application in 2024
11.4.7 ACS Dobfar Penem Antibiotics Revenue by Geographic Area in 2024
11.4.8 ACS Dobfar Penem Antibiotics SWOT Analysis
11.4.9 ACS Dobfar Recent Developments
11.5 Pfizer
11.5.1 Pfizer Corporation Information
11.5.2 Pfizer Business Overview
11.5.3 Pfizer Penem Antibiotics Product Features and Attributes
11.5.4 Pfizer Penem Antibiotics Revenue and Gross Margin (2020-2025)
11.5.5 Pfizer Penem Antibiotics Revenue by Product in 2024
11.5.6 Pfizer Penem Antibiotics Revenue by Application in 2024
11.5.7 Pfizer Penem Antibiotics Revenue by Geographic Area in 2024
11.5.8 Pfizer Penem Antibiotics SWOT Analysis
11.5.9 Pfizer Recent Developments
11.6 Eugia Pharma
11.6.1 Eugia Pharma Corporation Information
11.6.2 Eugia Pharma Business Overview
11.6.3 Eugia Pharma Penem Antibiotics Product Features and Attributes
11.6.4 Eugia Pharma Penem Antibiotics Revenue and Gross Margin (2020-2025)
11.6.5 Eugia Pharma Recent Developments
11.7 Venus Remedies
11.7.1 Venus Remedies Corporation Information
11.7.2 Venus Remedies Business Overview
11.7.3 Venus Remedies Penem Antibiotics Product Features and Attributes
11.7.4 Venus Remedies Penem Antibiotics Revenue and Gross Margin (2020-2025)
11.7.5 Venus Remedies Recent Developments
11.8 Sun Pharmaceutical
11.8.1 Sun Pharmaceutical Corporation Information
11.8.2 Sun Pharmaceutical Business Overview
11.8.3 Sun Pharmaceutical Penem Antibiotics Product Features and Attributes
11.8.4 Sun Pharmaceutical Penem Antibiotics Revenue and Gross Margin (2020-2025)
11.8.5 Sun Pharmaceutical Recent Developments
11.9 JW Pharmaceutical
11.9.1 JW Pharmaceutical Corporation Information
11.9.2 JW Pharmaceutical Business Overview
11.9.3 JW Pharmaceutical Penem Antibiotics Product Features and Attributes
11.9.4 JW Pharmaceutical Penem Antibiotics Revenue and Gross Margin (2020-2025)
11.9.5 JW Pharmaceutical Recent Developments
11.10 Aurobindo Pharma
11.10.1 Aurobindo Pharma Corporation Information
11.10.2 Aurobindo Pharma Business Overview
11.10.3 Aurobindo Pharma Penem Antibiotics Product Features and Attributes
11.10.4 Aurobindo Pharma Penem Antibiotics Revenue and Gross Margin (2020-2025)
11.10.5 Company Ten Recent Developments
11.11 Daiichi Sankyo
11.11.1 Daiichi Sankyo Corporation Information
11.11.2 Daiichi Sankyo Business Overview
11.11.3 Daiichi Sankyo Penem Antibiotics Product Features and Attributes
11.11.4 Daiichi Sankyo Penem Antibiotics Revenue and Gross Margin (2020-2025)
11.11.5 Daiichi Sankyo Recent Developments
11.12 Maruho
11.12.1 Maruho Corporation Information
11.12.2 Maruho Business Overview
11.12.3 Maruho Penem Antibiotics Product Features and Attributes
11.12.4 Maruho Penem Antibiotics Revenue and Gross Margin (2020-2025)
11.12.5 Maruho Recent Developments
11.13 Taiwan Biotech
11.13.1 Taiwan Biotech Corporation Information
11.13.2 Taiwan Biotech Business Overview
11.13.3 Taiwan Biotech Penem Antibiotics Product Features and Attributes
11.13.4 Taiwan Biotech Penem Antibiotics Revenue and Gross Margin (2020-2025)
11.13.5 Taiwan Biotech Recent Developments
11.14 Shenzhen Haibin Pharmaceutical
11.14.1 Shenzhen Haibin Pharmaceutical Corporation Information
11.14.2 Shenzhen Haibin Pharmaceutical Business Overview
11.14.3 Shenzhen Haibin Pharmaceutical Penem Antibiotics Product Features and Attributes
11.14.4 Shenzhen Haibin Pharmaceutical Penem Antibiotics Revenue and Gross Margin (2020-2025)
11.14.5 Shenzhen Haibin Pharmaceutical Recent Developments
11.15 Zhejiang Hisun Pharmaceutical
11.15.1 Zhejiang Hisun Pharmaceutical Corporation Information
11.15.2 Zhejiang Hisun Pharmaceutical Business Overview
11.15.3 Zhejiang Hisun Pharmaceutical Penem Antibiotics Product Features and Attributes
11.15.4 Zhejiang Hisun Pharmaceutical Penem Antibiotics Revenue and Gross Margin (2020-2025)
11.15.5 Zhejiang Hisun Pharmaceutical Recent Developments
11.16 Cspc Holdings
11.16.1 Cspc Holdings Corporation Information
11.16.2 Cspc Holdings Business Overview
11.16.3 Cspc Holdings Penem Antibiotics Product Features and Attributes
11.16.4 Cspc Holdings Penem Antibiotics Revenue and Gross Margin (2020-2025)
11.16.5 Cspc Holdings Recent Developments
11.17 Zhuhai United Laboratories
11.17.1 Zhuhai United Laboratories Corporation Information
11.17.2 Zhuhai United Laboratories Business Overview
11.17.3 Zhuhai United Laboratories Penem Antibiotics Product Features and Attributes
11.17.4 Zhuhai United Laboratories Penem Antibiotics Revenue and Gross Margin (2020-2025)
11.17.5 Zhuhai United Laboratories Recent Developments
11.18 Haikou Pharmaceutical Factory
11.18.1 Haikou Pharmaceutical Factory Corporation Information
11.18.2 Haikou Pharmaceutical Factory Business Overview
11.18.3 Haikou Pharmaceutical Factory Penem Antibiotics Product Features and Attributes
11.18.4 Haikou Pharmaceutical Factory Penem Antibiotics Revenue and Gross Margin (2020-2025)
11.18.5 Haikou Pharmaceutical Factory Recent Developments
11.19 Chia Tai Tianqing Pharmaceuticals
11.19.1 Chia Tai Tianqing Pharmaceuticals Corporation Information
11.19.2 Chia Tai Tianqing Pharmaceuticals Business Overview
11.19.3 Chia Tai Tianqing Pharmaceuticals Penem Antibiotics Product Features and Attributes
11.19.4 Chia Tai Tianqing Pharmaceuticals Penem Antibiotics Revenue and Gross Margin (2020-2025)
11.19.5 Chia Tai Tianqing Pharmaceuticals Recent Developments
11.20 Jiangsu Simcere Pharmaceutical
11.20.1 Jiangsu Simcere Pharmaceutical Corporation Information
11.20.2 Jiangsu Simcere Pharmaceutical Business Overview
11.20.3 Jiangsu Simcere Pharmaceutical Penem Antibiotics Product Features and Attributes
11.20.4 Jiangsu Simcere Pharmaceutical Penem Antibiotics Revenue and Gross Margin (2020-2025)
11.20.5 Jiangsu Simcere Pharmaceutical Recent Developments
12 Penem AntibioticsIndustry Chain Analysis
12.1 Penem Antibiotics Industry Chain
12.2 Upstream Analysis
12.2.1 Upstream Key Suppliers
12.3 Middlestream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Penem Antibiotics Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Penem Antibiotics Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
FEATURED COMPANIES
Sumitomo Pharma
Merck Sharp & Dohme
Savior Lifetec
ACS Dobfar
Pfizer Inc
Eugia Pharma
Venus Remedies
Sun Pharmaceutical
JW Pharmaceutical
Aurobindo Pharma
Daiichi Sankyo
Maruho
Taiwan Biotech
Shenzhen Haibin Pharmaceutical
Zhejiang Hisun Pharmaceutical
Cspc Holdings
Zhuhai United Laboratories
Haikou Pharmaceutical Factory
Jiangsu Simcere Pharmaceutical
Chia Tai Tianqing Pharmaceuticals
Merck Sharp & Dohme
List of Tables
 Table 1. Global Penem Antibiotics Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
 Table 2. Global Penem Antibiotics Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
 Table 3. Global Penem Antibiotics Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 4. Global Penem Antibiotics Revenue by Region (2020-2025) & (US$ Million)
 Table 5. Global Penem Antibiotics Revenue by Region (2026-2031) & (US$ Million)
 Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 7. Global Penem Antibiotics Revenue by Players (2020-2025) & (US$ Million)
 Table 8. Global Penem Antibiotics Revenue Market Share by Players (2020-2025)
 Table 9. Global Key Players’Ranking Shift (2023 vs. 2024) (Based on Revenue)
 Table 10. Global Penem Antibiotics by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Penem Antibiotics as of 2024)
 Table 11. Global Penem Antibiotics Average Gross Margin (%) by Player (2020 VS 2024)
 Table 12. Global Penem Antibiotics Companies Headquarters
 Table 13. Global Penem Antibiotics Market Concentration Ratio (CR5 and HHI)
 Table 14. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
 Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
 Table 16. Global Penem Antibiotics Revenue by Type (2020-2025) & (US$ Million)
 Table 17. Global Penem Antibiotics Revenue by Type (2026-2031) & (US$ Million)
 Table 18. Key Product Attributes and Differentiation
 Table 19. Global Penem Antibiotics Revenue by Application (2020-2025) & (US$ Million)
 Table 20. Global Penem Antibiotics Revenue by Application (2026-2031) & (US$ Million)
 Table 21. Penem Antibiotics High-Growth Sectors Demand CAGR (2024-2031)
 Table 22. Top Customers by Region
 Table 23. Top Customers by Application
 Table 24. North America Penem Antibiotics Growth Accelerators and Market Barriers
 Table 25. North America Penem Antibiotics Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 26. Europe Penem Antibiotics Growth Accelerators and Market Barriers
 Table 27. Europe Penem Antibiotics Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 28. Asia-Pacific Penem Antibiotics Growth Accelerators and Market Barriers
 Table 29. Asia-Pacific Penem Antibiotics Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 30. Central and South America Penem Antibiotics Investment Opportunities and Key Challenges
 Table 31. Central and South America Penem Antibiotics Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 32. Middle East and Africa Penem Antibiotics Investment Opportunities and Key Challenges
 Table 33. Middle East and Africa Penem Antibiotics Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 34. Sumitomo Pharma Corporation Information
 Table 35. Sumitomo Pharma Description and Major Businesses
 Table 36. Sumitomo Pharma Product Features and Attributes
 Table 37. Sumitomo Pharma Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 38. Sumitomo Pharma Revenue Proportion by Product in 2024
 Table 39. Sumitomo Pharma Revenue Proportion by Application in 2024
 Table 40. Sumitomo Pharma Revenue Proportion by Geographic Area in 2024
 Table 41. Sumitomo Pharma Penem Antibiotics SWOT Analysis
 Table 42. Sumitomo Pharma Recent Developments
 Table 43. Merck Sharp & Dohme Corporation Information
 Table 44. Merck Sharp & Dohme Description and Major Businesses
 Table 45. Merck Sharp & Dohme Product Features and Attributes
 Table 46. Merck Sharp & Dohme Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 47. Merck Sharp & Dohme Revenue Proportion by Product in 2024
 Table 48. Merck Sharp & Dohme Revenue Proportion by Application in 2024
 Table 49. Merck Sharp & Dohme Revenue Proportion by Geographic Area in 2024
 Table 50. Merck Sharp & Dohme Penem Antibiotics SWOT Analysis
 Table 51. Merck Sharp & Dohme Recent Developments
 Table 52. Savior Lifetec Corporation Information
 Table 53. Savior Lifetec Description and Major Businesses
 Table 54. Savior Lifetec Product Features and Attributes
 Table 55. Savior Lifetec Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 56. Savior Lifetec Revenue Proportion by Product in 2024
 Table 57. Savior Lifetec Revenue Proportion by Application in 2024
 Table 58. Savior Lifetec Revenue Proportion by Geographic Area in 2024
 Table 59. Savior Lifetec Penem Antibiotics SWOT Analysis
 Table 60. Savior Lifetec Recent Developments
 Table 61. ACS Dobfar Corporation Information
 Table 62. ACS Dobfar Description and Major Businesses
 Table 63. ACS Dobfar Product Features and Attributes
 Table 64. ACS Dobfar Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 65. ACS Dobfar Revenue Proportion by Product in 2024
 Table 66. ACS Dobfar Revenue Proportion by Application in 2024
 Table 67. ACS Dobfar Revenue Proportion by Geographic Area in 2024
 Table 68. ACS Dobfar Penem Antibiotics SWOT Analysis
 Table 69. ACS Dobfar Recent Developments
 Table 70. Pfizer Corporation Information
 Table 71. Pfizer Description and Major Businesses
 Table 72. Pfizer Product Features and Attributes
 Table 73. Pfizer Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 74. Pfizer Revenue Proportion by Product in 2024
 Table 75. Pfizer Revenue Proportion by Application in 2024
 Table 76. Pfizer Revenue Proportion by Geographic Area in 2024
 Table 77. Pfizer Penem Antibiotics SWOT Analysis
 Table 78. Pfizer Recent Developments
 Table 79. Eugia Pharma Corporation Information
 Table 80. Eugia Pharma Description and Major Businesses
 Table 81. Eugia Pharma Product Features and Attributes
 Table 82. Eugia Pharma Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 83. Eugia Pharma Recent Developments
 Table 84. Venus Remedies Corporation Information
 Table 85. Venus Remedies Description and Major Businesses
 Table 86. Venus Remedies Product Features and Attributes
 Table 87. Venus Remedies Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 88. Venus Remedies Recent Developments
 Table 89. Sun Pharmaceutical Corporation Information
 Table 90. Sun Pharmaceutical Description and Major Businesses
 Table 91. Sun Pharmaceutical Product Features and Attributes
 Table 92. Sun Pharmaceutical Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 93. Sun Pharmaceutical Recent Developments
 Table 94. JW Pharmaceutical Corporation Information
 Table 95. JW Pharmaceutical Description and Major Businesses
 Table 96. JW Pharmaceutical Product Features and Attributes
 Table 97. JW Pharmaceutical Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 98. JW Pharmaceutical Recent Developments
 Table 99. Aurobindo Pharma Corporation Information
 Table 100. Aurobindo Pharma Description and Major Businesses
 Table 101. Aurobindo Pharma Product Features and Attributes
 Table 102. Aurobindo Pharma Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 103. Aurobindo Pharma Recent Developments
 Table 104. Daiichi Sankyo Corporation Information
 Table 105. Daiichi Sankyo Description and Major Businesses
 Table 106. Daiichi Sankyo Product Features and Attributes
 Table 107. Daiichi Sankyo Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 108. Daiichi Sankyo Recent Developments
 Table 109. Maruho Corporation Information
 Table 110. Maruho Description and Major Businesses
 Table 111. Maruho Product Features and Attributes
 Table 112. Maruho Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 113. Maruho Recent Developments
 Table 114. Taiwan Biotech Corporation Information
 Table 115. Taiwan Biotech Description and Major Businesses
 Table 116. Taiwan Biotech Product Features and Attributes
 Table 117. Taiwan Biotech Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 118. Taiwan Biotech Recent Developments
 Table 119. Shenzhen Haibin Pharmaceutical Corporation Information
 Table 120. Shenzhen Haibin Pharmaceutical Description and Major Businesses
 Table 121. Shenzhen Haibin Pharmaceutical Product Features and Attributes
 Table 122. Shenzhen Haibin Pharmaceutical Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 123. Shenzhen Haibin Pharmaceutical Recent Developments
 Table 124. Zhejiang Hisun Pharmaceutical Corporation Information
 Table 125. Zhejiang Hisun Pharmaceutical Description and Major Businesses
 Table 126. Zhejiang Hisun Pharmaceutical Product Features and Attributes
 Table 127. Zhejiang Hisun Pharmaceutical Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 128. Zhejiang Hisun Pharmaceutical Recent Developments
 Table 129. Cspc Holdings Corporation Information
 Table 130. Cspc Holdings Description and Major Businesses
 Table 131. Cspc Holdings Product Features and Attributes
 Table 132. Cspc Holdings Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 133. Cspc Holdings Recent Developments
 Table 134. Zhuhai United Laboratories Corporation Information
 Table 135. Zhuhai United Laboratories Description and Major Businesses
 Table 136. Zhuhai United Laboratories Product Features and Attributes
 Table 137. Zhuhai United Laboratories Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 138. Zhuhai United Laboratories Recent Developments
 Table 139. Haikou Pharmaceutical Factory Corporation Information
 Table 140. Haikou Pharmaceutical Factory Description and Major Businesses
 Table 141. Haikou Pharmaceutical Factory Product Features and Attributes
 Table 142. Haikou Pharmaceutical Factory Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 143. Haikou Pharmaceutical Factory Recent Developments
 Table 144. Chia Tai Tianqing Pharmaceuticals Corporation Information
 Table 145. Chia Tai Tianqing Pharmaceuticals Description and Major Businesses
 Table 146. Chia Tai Tianqing Pharmaceuticals Product Features and Attributes
 Table 147. Chia Tai Tianqing Pharmaceuticals Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 148. Chia Tai Tianqing Pharmaceuticals Recent Developments
 Table 149. Jiangsu Simcere Pharmaceutical Corporation Information
 Table 150. Jiangsu Simcere Pharmaceutical Description and Major Businesses
 Table 151. Jiangsu Simcere Pharmaceutical Product Features and Attributes
 Table 152. Jiangsu Simcere Pharmaceutical Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 153. Jiangsu Simcere Pharmaceutical Recent Developments
 Table 154. Raw Materials Key Suppliers
 Table 155. Distributors List
 Table 156. Market Trends and Market Evolution
 Table 157. Market Drivers and Opportunities
 Table 158. Market Challenges, Risks, and Restraints
 Table 159. Research Programs/Design for This Report
 Table 160. Key Data Information from Secondary Sources
 Table 161. Key Data Information from Primary Sources


List of Figures
 Figure 1. Penem Antibiotics Product Picture
 Figure 2. Global Penem Antibiotics Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 3. Meropenem Product Picture
 Figure 4. Imipenem Product Picture
 Figure 5. Biapenem Product Picture
 Figure 6. Ertapenem Product Picture
 Figure 7. Others Product Picture
 Figure 8. Global Penem Antibiotics Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 9. Hospital
 Figure 10. Clinic
 Figure 11. Others
 Figure 12. Penem Antibiotics Report Years Considered
 Figure 13. Global Penem Antibiotics Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 14. Global Penem Antibiotics Revenue (2020-2031) & (US$ Million)
 Figure 15. Global Penem Antibiotics Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Figure 16. Global Penem Antibiotics Revenue Market Share by Region (2020-2031)
 Figure 17. Global Penem Antibiotics Revenue Market Share Ranking (2024)
 Figure 18. Tier Distribution by Revenue Contribution (2020 VS 2024)
 Figure 19. Meropenem Revenue Market Share by Player in 2024
 Figure 20. Imipenem Revenue Market Share by Player in 2024
 Figure 21. Biapenem Revenue Market Share by Player in 2024
 Figure 22. Ertapenem Revenue Market Share by Player in 2024
 Figure 23. Others Revenue Market Share by Player in 2024
 Figure 24. Global Penem Antibiotics Revenue Market Share by Type (2020-2031)
 Figure 25. Global Penem Antibiotics Revenue Market Share by Application (2020-2031)
 Figure 26. North America Penem Antibiotics Revenue YoY (2020-2031) & (US$ Million)
 Figure 27. North America Top 5 Players Penem Antibiotics Revenue (US$ Million) in 2024
 Figure 28. North America Penem Antibiotics Revenue (US$ Million) by Type (2020 - 2031)
 Figure 29. North America Penem Antibiotics Revenue (US$ Million) by Application (2020-2031)
 Figure 30. US Penem Antibiotics Revenue (2020-2031) & (US$ Million)
 Figure 31. Canada Penem Antibiotics Revenue (2020-2031) & (US$ Million)
 Figure 32. Mexico Penem Antibiotics Revenue (2020-2031) & (US$ Million)
 Figure 33. Europe Penem Antibiotics Revenue YoY (2020-2031) & (US$ Million)
 Figure 34. Europe Top 5 Players Penem Antibiotics Revenue (US$ Million) in 2024
 Figure 35. Europe Penem Antibiotics Revenue (US$ Million) by Type (2020-2031)
 Figure 36. Europe Penem Antibiotics Revenue (US$ Million) by Application (2020-2031)
 Figure 37. Germany Penem Antibiotics Revenue (2020-2031) & (US$ Million)
 Figure 38. France Penem Antibiotics Revenue (2020-2031) & (US$ Million)
 Figure 39. U.K. Penem Antibiotics Revenue (2020-2031) & (US$ Million)
 Figure 40. Italy Penem Antibiotics Revenue (2020-2031) & (US$ Million)
 Figure 41. Russia Penem Antibiotics Revenue (2020-2031) & (US$ Million)
 Figure 42. Asia-Pacific Penem Antibiotics Revenue YoY (2020-2031) & (US$ Million)
 Figure 43. Asia-Pacific Top 8 Players Penem Antibiotics Revenue (US$ Million) in 2024
 Figure 44. Asia-Pacific Penem Antibiotics Revenue (US$ Million) by Type (2020-2031)
 Figure 45. Asia-Pacific Penem Antibiotics Revenue (US$ Million) by Application (2020-2031)
 Figure 46. Indonesia Penem Antibiotics Revenue (2020-2031) & (US$ Million)
 Figure 47. Japan Penem Antibiotics Revenue (2020-2031) & (US$ Million)
 Figure 48. South Korea Penem Antibiotics Revenue (2020-2031) & (US$ Million)
 Figure 49. Australia Penem Antibiotics Revenue (2020-2031) & (US$ Million)
 Figure 50. India Penem Antibiotics Revenue (2020-2031) & (US$ Million)
 Figure 51. Indonesia Penem Antibiotics Revenue (2020-2031) & (US$ Million)
 Figure 52. Vietnam Penem Antibiotics Revenue (2020-2031) & (US$ Million)
 Figure 53. Malaysia Penem Antibiotics Revenue (2020-2031) & (US$ Million)
 Figure 54. Philippines Penem Antibiotics Revenue (2020-2031) & (US$ Million)
 Figure 55. Singapore Penem Antibiotics Revenue (2020-2031) & (US$ Million)
 Figure 56. Central and South America Penem Antibiotics Revenue YoY (2020-2031) & (US$ Million)
 Figure 57. Central and South America Top 5 Players Penem Antibiotics Revenue (US$ Million) in 2024
 Figure 58. Central and South America Penem Antibiotics Revenue (US$ Million) by Type (2020-2031)
 Figure 59. Central and South America Penem Antibiotics Revenue (US$ Million) by Application (2020-2031)
 Figure 60. Brazil Penem Antibiotics Revenue (2020-2025) & (US$ Million)
 Figure 61. Argentina Penem Antibiotics Revenue (2020-2025) & (US$ Million)
 Figure 62. Middle East and Africa Penem Antibiotics Revenue YoY (2020-2031) & (US$ Million)
 Figure 63. Middle East and Africa Top 5 Players Penem Antibiotics Revenue (US$ Million) in 2024
 Figure 64. South America Penem Antibiotics Revenue (US$ Million) by Type (2020-2031)
 Figure 65. Middle East and Africa Penem Antibiotics Revenue (US$ Million) by Application (2020-2031)
 Figure 66. GCC Countries Penem Antibiotics Revenue (2020-2025) & (US$ Million)
 Figure 67. Israel Penem Antibiotics Revenue (2020-2025) & (US$ Million)
 Figure 68. Egypt Penem Antibiotics Revenue (2020-2025) & (US$ Million)
 Figure 69. South Africa Penem Antibiotics Revenue (2020-2025) & (US$ Million)
 Figure 70. Penem Antibiotics Industry Chain Mapping
 Figure 71. Channels of Distribution (Direct Vs Distribution)
 Figure 72. Bottom-up and Top-down Approaches for This Report
 Figure 73. Data Triangulation
 Figure 74. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$4900

This license allows only one user to access the PDF.
Electronic (PDF)

$7350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$9800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Strategic Venue Partners

SIMILAR REPORTS

Global Penem APIs Market Research Report 2024
Global Penem APIs and Intermediates Market Research Report 2024
Global Carbapenems Drug Intermediates Market Research Report 2024
Global Beta lactam and Beta lactamase Inhibitors Market Research Report 2025
Global Penem Antibiotic Intermediates Market Research Report 2024
Global Carbapenem Market Insights Forecast to 2030
Global Penem Drug Intermediates Market Research Report 2024
Global Oxycephem Antibiotics Market Research Report 2024
Global Carbapenem Drugs Market Research Report 2024
Global Enzymes for β lactam Antibiotics Market Research Report 2024
Global β Lactam Antibiotics Market Research Report 2025
Cephalosporin Market
Global Carbapenem resistant Enterobacteriaceae Testing Market Research Report 2024
Global Non beta lactam Antibiotics Market Research Report 2024
Carbapenem Based Antibiotics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Ceftazidime Market Insights Forecast to 2030
Global Cephalosporin Antibiotic Side Chain Intermediates Market Research Report 2024
β Lactamaseinhibitors Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Cefepime Market Research Report 2024
Ampicillin Solution Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions